Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets increased its holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 608.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,900,970 shares of the company's stock after purchasing an additional 2,491,530 shares during the period. BNP Paribas Financial Markets owned approximately 0.35% of Dr. Reddy's Laboratories worth $45,806,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in Dr. Reddy's Laboratories by 109.3% during the 3rd quarter. Geode Capital Management LLC now owns 13,254 shares of the company's stock valued at $1,053,000 after buying an additional 6,920 shares during the period. GAMMA Investing LLC lifted its stake in Dr. Reddy's Laboratories by 369.9% in the fourth quarter. GAMMA Investing LLC now owns 6,799 shares of the company's stock worth $107,000 after purchasing an additional 5,352 shares during the last quarter. Nordea Investment Management AB boosted its position in shares of Dr. Reddy's Laboratories by 441.8% during the fourth quarter. Nordea Investment Management AB now owns 125,363 shares of the company's stock valued at $1,992,000 after buying an additional 102,226 shares during the period. Aprio Wealth Management LLC grew its stake in shares of Dr. Reddy's Laboratories by 515.6% during the fourth quarter. Aprio Wealth Management LLC now owns 18,807 shares of the company's stock valued at $297,000 after buying an additional 15,752 shares during the last quarter. Finally, Harbour Capital Advisors LLC raised its holdings in shares of Dr. Reddy's Laboratories by 400.0% in the fourth quarter. Harbour Capital Advisors LLC now owns 25,100 shares of the company's stock worth $388,000 after buying an additional 20,080 shares during the period. Hedge funds and other institutional investors own 3.85% of the company's stock.

Analysts Set New Price Targets

Separately, StockNews.com raised Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday.

Dr. Reddy's Laboratories Stock Up 1.8 %

NYSE RDY traded up $0.24 on Friday, reaching $13.42. 2,669,798 shares of the stock traded hands, compared to its average volume of 1,487,128. Dr. Reddy's Laboratories Limited has a 12 month low of $12.26 and a 12 month high of $16.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The company has a fifty day moving average price of $13.29 and a 200-day moving average price of $14.07. The company has a market cap of $11.20 billion, a price-to-earnings ratio of 21.37 and a beta of 0.33.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its earnings results on Friday, May 9th. The company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.02. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. The company had revenue of $996.17 million for the quarter, compared to analysts' expectations of $83.70 billion. As a group, research analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.